Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.82M 3.34M 3.09M 2.85M 367M 5.48M 36.87M 14.42M 180M 14.34M 14.02M 619M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.47M 3.92M 3.62M 3.34M 430M 6.41M 43.19M 16.89M 210M 16.8M 16.43M 725M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -1.05% | +1.39% | +3.15% | +6.98% | 50.61B | |
| +0.55% | -2.88% | +382.07% | +593.81% | 39.11B | |
| +0.13% | -0.19% | +29.79% | -6.00% | 34.64B | |
| +0.86% | -0.78% | +21.58% | +56.15% | 33.79B | |
| -1.31% | -3.03% | +2.51% | +25.24% | 26.89B | |
| +0.13% | -0.52% | - | - | 16.47B | |
| +1.13% | -1.85% | +67.36% | +120.46% | 15.14B | |
| -0.72% | +0.12% | +14.69% | +16.95% | 13.85B | |
| +1.13% | -0.44% | +12.34% | -31.79% | 12.72B | |
| Average | +1.20% | -1.54% | +66.69% | +97.72% | 27.02B | |
| Weighted average by Cap. | -0.04% | -1.14% | +80.75% | +121.71% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.08M -13.21M -12.21M -11.27M -1.45B -21.64M -146M -56.97M -710M -56.68M -55.41M -2.45B | 4.21M 2.99M 2.62M 2.42M 2.24M 288M 4.29M 28.92M 11.31M 141M 11.25M 11M 486M |
| Net Debt | 704K 500K 439K 405K 374K 48.14M 718K 4.84M 1.89M 23.56M 1.88M 1.84M 81.22M | 920K 654K 573K 530K 489K 62.91M 938K 6.32M 2.47M 30.79M 2.46M 2.4M 106M |
Employees
-
Choose MarketScreener 
